TrimRx vs Hims: Complete 2026 Comparison

Introduction

Hims is the most heavily marketed telehealth brand in the US. Its weight loss vertical sells compounded semaglutide as a key offering, alongside oral options and lifestyle support. TrimRx is a smaller, more focused player that prescribes compounded semaglutide and tirzepatide without the broad lifestyle brand wrapper.

Both target adults pursuing weight loss with GLP-1 medication, but their pricing, audience, and clinical models differ significantly. The Novo Nordisk lawsuit against compounding pharmacies, plus the FDA’s resolution of the semaglutide shortage, has changed how Hims operates in 2026.

This comparison covers pricing, medications, clinician access, and the regulatory backdrop so you can pick the right program.

At TrimRx, we believe that understanding your options is the first step toward a more manageable health journey. You can take the free assessment quiz if you’re ready to see whether a personalized program is a fit for you.

What Is Hims Weight Loss?

Hims is a publicly traded US telehealth platform (HIMS on NYSE). Its weight loss vertical launched in 2023 and grew rapidly during the GLP-1 boom. The company offers compounded semaglutide injections, an oral GLP-1 alternative, and lifestyle support through its app.

Quick Answer: Hims Weight Loss prescribes compounded semaglutide at $199-$249 per month entry pricing

Hims’ pricing for compounded semaglutide has fluctuated based on supply and regulatory status, ranging from $199 to $349 per month depending on plan tier and active promotions. The platform’s broad consumer brand drives heavy advertising spend.

The clinical model is async-first with licensed clinicians who review intake and prescribe. Hims also markets to a broader audience than weight-specific programs, including patients pursuing hair loss treatment, ED medications, and skincare.

What Is TrimRx?

TrimRx is a focused telehealth platform that prescribes compounded semaglutide and tirzepatide. The intake is a free assessment quiz followed by clinician review and personalized treatment plan. Medication ships from licensed US 503A and 503B compounding pharmacies.

The platform is unisex and focused exclusively on weight management with GLP-1 medications. No hair loss products, no ED medications, no skincare. The narrower catalog means clinicians work in one therapeutic area.

Pricing is transparent at intake: semaglutide starts around $199 per month, tirzepatide around $299. Quarterly and annual prepay options reduce the effective rate by 10-20%.

How Do TrimRx and Hims Compare on Price?

Hims and TrimRx semaglutide entry pricing is similar, both around $199 per month. Hims runs frequent promotions that drop first-month pricing below standard rates, with standard rates kicking in afterward.

For tirzepatide, TrimRx has a clear advantage: $299 per month standard pricing. Hims doesn’t routinely offer tirzepatide as a standard option, focusing instead on semaglutide.

Annual cost for typical semaglutide patient: roughly $2,400-$3,500 at both providers. Tirzepatide patients who specifically want that medication will need TrimRx or another provider that offers it.

Which Medications Does Each Provider Offer?

Hims primarily offers compounded semaglutide injections. There’s an oral GLP-1 option in some markets. Hims doesn’t routinely sell tirzepatide, brand-name Wegovy®, or brand-name Zepbound® at standard cash-pay rates.

TrimRx offers compounded semaglutide and compounded tirzepatide. No oral options, no brand-name, no other obesity medications.

If you specifically want tirzepatide (the medication that produced 20.9% weight loss in SURMOUNT-1, Jastreboff et al. 2022 NEJM, versus 14.9% for semaglutide in STEP 1), TrimRx is the path. Tirzepatide also won FDA approval for obstructive sleep apnea in December 2024 (SURMOUNT-OSA) and outperformed semaglutide head-to-head for HbA1c and weight in SURPASS-2.

How Does the Clinician Experience Compare?

Both providers run async-first clinical models. Patients message clinicians through a patient portal, get replies within a business day for non-urgent questions, and don’t typically have synchronous video visits unless required by state law.

Hims’ clinical staff handles multiple therapeutic areas (weight, hair, ED, mental health) across the broader Hims platform. Clinicians assigned to weight loss specifically work in that area, but the overall platform isn’t weight-focused.

TrimRx clinicians work exclusively in compounded GLP-1 prescribing. The narrower focus generally produces more specific titration advice and side effect management.

What’s Included with Each Program?

Hims weight loss bundles medication, clinician access, shipping, and access to its app with educational content. The Hims app integrates with the broader Hims product ecosystem, which can be useful if you’re already a customer for other products.

TrimRx bundles medication, clinician messaging, dose titration support, and shipping. No proprietary app, no broader product ecosystem.

If you’re already a Hims customer for other products, the unified account is convenient. If you just want compounded GLP-1s, TrimRx is the focused option.

How Does the Regulatory Backdrop Affect Both Providers?

The FDA declared the semaglutide shortage resolved in early 2025, which limits the legal basis for compounding pharmacies to mass-produce compounded semaglutide. Compounding remains legal for individualized patient prescriptions and certain other exemptions, but the broad shortage-driven compounding window has narrowed.

Novo Nordisk has filed lawsuits against multiple compounding-based telehealth providers. Hims has been a named party in some litigation. The regulatory and legal status continues to evolve.

Both Hims and TrimRx continue operating under current legal frameworks, sourcing from licensed US 503A and 503B pharmacies. Patients should monitor regulatory updates for any changes that affect supply.

Key Takeaway: Hims doesn’t offer tirzepatide as a standard option; TrimRx does

How Do Customer Reviews Compare?

Hims has hundreds of thousands of public reviews across its full product line. Weight loss-specific reviews praise convenience, marketing, and entry pricing. Complaints cluster around shipping delays during peak demand, confusion about post-promo pricing, and cancellation friction.

TrimRx reviews praise pricing transparency, clinician responsiveness, and focused product. Complaints cluster around limited in-app coaching content.

Both providers sit in the 4.0-4.5 star range on major review platforms, comparable to other major compounded GLP-1 services.

Which Is Better for Weight Loss Outcomes?

The active ingredients are the same: compounded semaglutide is semaglutide regardless of provider. STEP 1 (Wilding et al. 2021 NEJM) outcomes apply to the active ingredient at appropriate dosing.

Real-world reviews at both providers report weight loss in the 10-15% range over 6+ months on consistent dosing, matching the clinical trial trajectory. Tirzepatide users (only available at TrimRx of these two) report higher weight loss matching SURMOUNT-1’s 20.9% benchmark.

Patient adherence and titration to therapeutic dose matter more than provider brand. STEP 1 showed weight loss accelerates after the first 20 weeks; patients who stop early see proportionally smaller results.

Which One Should You Choose?

Choose Hims if you want a heavily marketed brand with broader product offerings, you already use Hims for other categories, or you specifically want compounded semaglutide without considering tirzepatide.

Choose TrimRx if you want a focused GLP-1 program, you specifically want access to compounded tirzepatide, or you prefer a clinician model focused on weight management only.

Run the free TrimRx assessment quiz for a personalized price quote. Compare to Hims’ intake quote. Both intakes are free, so comparison shopping costs nothing.

How Does the Regulatory Environment Shape Both Providers?

The FDA declared the semaglutide shortage resolved in early 2025, which narrowed the broad shortage-driven compounding pathway. Compounding for individualized patient prescriptions and certain other exemptions continues legally. Both Hims and TrimRx operate under these frameworks.

Novo Nordisk filed lawsuits against compounding-based telehealth providers including Hims in 2024-2025. The legal landscape continues to evolve. Patients should monitor regulatory updates; changes affecting supply or legality of compounded semaglutide would affect both providers similarly.

Tirzepatide’s compounding status faces similar evolving regulatory scrutiny. Eli Lilly has pursued legal action against some compounding-based providers as well. Patients on tirzepatide through TrimRx should also monitor regulatory updates.

What Do the Most Recent Cardiovascular and Kidney Trials Add to Both Providers’ Clinical Value?

SELECT (Lincoff et al. 2023 NEJM) showed semaglutide reduced major adverse cardiovascular events by 20% in adults with overweight or obesity and established cardiovascular disease. FLOW (Perkovic et al. 2024 NEJM) showed 24% reduction in kidney disease progression or death from kidney/CV causes in type 2 diabetes with CKD.

For patients with these conditions, semaglutide’s clinical value extends well beyond weight loss. Both Hims and TrimRx clinicians can discuss these benefits during intake, though neither provider focuses marketing on cardiovascular or kidney outcomes specifically.

SURMOUNT-OSA earned tirzepatide FDA approval for moderate-to-severe obstructive sleep apnea in December 2024. Patients with OSA have additional clinical reason to consider tirzepatide, which is available at TrimRx but not Hims.

Bottom line: Both rely on the same clinical evidence: STEP 1, SURMOUNT-1, SELECT, FLOW

FAQ

Is Hims Legit?

Yes. Hims is a publicly traded US telehealth platform using licensed clinicians and compounded medications from licensed US pharmacies. The company is regulated as a public company with SEC reporting requirements.

Does Hims Offer Tirzepatide?

Generally no, not as a standard option. Hims focuses on compounded semaglutide. TrimRx is one of the more accessible providers for compounded tirzepatide.

Which Is Cheaper?

Entry pricing for compounded semaglutide is similar, both around $199 per month. Promotions can shift the leader month-to-month. Tirzepatide patients have a clearer path through TrimRx.

Are the Medications the Same?

The active ingredient (semaglutide) is the same at both providers. Both source from licensed US compounding pharmacies. Inactive ingredients may vary by pharmacy partner.

Does Either Accept Insurance?

No. Both are cash-pay only. HSA and FSA reimbursement is sometimes possible when medication is prescribed for diagnosed obesity (BMI 30+) or type 2 diabetes.

What About Hims’ Broader Product Catalog?

Hims sells hair loss treatments, ED medications, mental health support, and skincare alongside weight loss. TrimRx focuses only on GLP-1 weight management.

Is Compounded Semaglutide Still Legal?

Yes, under current frameworks for individualized patient prescriptions and certain other exemptions. The FDA’s resolution of the semaglutide shortage narrowed the broad shortage-driven compounding pathway, but compounding for individual patients continues legally. Monitor regulatory updates.

Disclaimer: This content is for informational purposes only and does not constitute medical advice. It is not intended to diagnose, treat, cure, or prevent any disease or condition. Individual results may vary. Always consult a qualified healthcare professional before starting any weight loss program or medication.